Protherics--Empfohlener EK unter 55p - 500 Beiträge pro Seite

[BrauchGeld]

Hallo

Protherics die nächste Perle aus U.K.
Die Aktie ist auf aktuellen niveau einfach so sehr unterbewertet das ich sofort zu 53p eingekauft habe.
Empfohlener EK bis max.60p(0,88€) und VK ab 100p
Was mich überzeugt hat:

1.Massive Aktienkäufe
2.Zwei Produkte(CroFab,DigiFab) auf dem Markt
3.Sehr aussichtsreiche Pipeline(vor allem CytoFab startet bald Phase3)milliarden dollar Markt.
4.Voraxaze steht kurz vor der Zulassung (1.Quartal 2006) mit über 200 mio$ markt.
5.Niedrige Bewertung mit 144mio pfund ---209mio€


Homepage:
http://www.protherics.com/products/Clinical_Development.asp

Protherics plc
Recommendation BUY

Reasons to be cheerful
We see a number of powerful reasons for optimism on Protherics. The company’s two marketed products continue to enjoy double-digit top-line growth with the prospect of substantial increases in gross margins. Voraxaze, which, we believe, is within 1-2 months of regulatory submission, could look forward to far more aggressive use by physicians than initially anticipated. Negotiations in relation to the partnering of the sepsis product, CytoFab, appear to be reaching a critical phase with potential partners.

· Growth in top-line and margins for CroFab and DigiFab

Excluding the effects of a weakened dollar and a scheduled decrease in royalties from 60% to 50%, there was combined volume and price growth of 10% in Protherics’ snake bite antidote, CroFab, and heart drug antidote, DigiFab. In addition, CroFab margins should move from 45% to 70% in 2007/8 as a result of improvements in manufacturing efficiencies.

· Physicians indicate enthusiasm for extended Voraxaze use

Voraxaze has been developed to combat the toxic effects of the widely used cancer drug, methotrexate. With studies completed, regulatory filing should happen in 1-2 months. Feedback from pre-launch activities indicates that oncologists may already be keen to extend beyond acute emergency use to routine use with methotrexate. This so called “planned use” could significantly boost the market for Voraxaze beyond its initial $200m acute care market.

· Optimism on CytoFab licensing

Protherics appears to have entered a critical phase in partnering negotiations with several potential partners on its sepsis therapy, CytoFab. With encouraging clinical data, an established manufacturing capability as well as capacity, we remain optimistic that the company will achieve its stated goal of a deal by the end of 2005.

· Substantial upside and newsflow

We value the emergency medicines business alone at 76p/share. This excludes CytoFab, the Prolarix cancer drug, and the angiotensin vaccine, which are thus pure upside. The next six months newsflow includes filing of Voraxaze, licensing of CytoFab, and potential boosts to the 2006 bottom-line through IFRS changes to goodwill and capitalisation of R&D. Licensing of CytoFab alone would bring our fair value to 140p, or ~2-3 times the current price. We retain our BUY rating and 95p target."


Und nun lass mein Konto weiter wachsen Baby.

[BrauchGeld]

Fidelity,Axa,Aviva und andere nahmhafte Investoren sind hier mit vertreten.
Protherics ist auch seit ein paar wochen an der Nasdaq (PTIL)gelistet.


PROTHERICS PLC

VORAXAZE(TM) EU MARKETING AUTHORISATION SUBMITTED


28 July 2005: Protherics PLC (`Protherics` or the `Company`), the international
biopharmaceutical company focused on critical care and oncology, today announces
that it has submitted a marketing authorisation application (`MAA`) in the
European Union (`EU`) for Voraxaze(TM). Voraxaze is an adjunctive therapy for
patients experiencing, or at risk of, toxicity from methotrexate (`MTX`), a
widely used anti-cancer agent.

The clinical trials in Europe and the US have shown that Voraxaze rapidly and
predictably clears MTX from the blood of patients in whom its elimination has
been delayed. This reduces the risk of serious toxicities and death which can
result from prolonged exposure to MTX. Voraxaze was very well-tolerated, with
only 16 transient adverse events reported by 12 of 230 patients.

Voraxaze is currently available for use in Europe on a named patient basis where
it has been used successfully in major EU cancer centres over the past 2 years.
Medical practitioners are able to request and purchase un-licensed drugs for
specific patients where there is unmet clinical need. There are no other drug
treatments available for patients experiencing delayed elimination of MTX.

The MAA was submitted today to the regulatory agencies in Sweden and the UK, the
rapporteur and co-rapporteur in the EU. Protherics is planning to launch
Voraxaze in the EU in 2006 through the Company`s own in-house sales and
marketing operation.

Voraxaze will initially be used as an intervention to treat those patients
experiencing, or at risk of, significant toxicity due to MTX following high-dose
therapy. In the future, Voraxaze may prove suitable for more routine adjunctive
use with high-dose MTX to reduce the risk of toxicity and thereby allow
optimisation of MTX therapy. Protherics estimates that the global market
opportunity for Voraxaze could be up to $200 million.

Andrew Heath, Chief Executive of Protherics said:

`Voraxaze is an important drug that holds significant promise for cancer
therapy. By predictably and rapidly clearing MTX, Voraxaze allows clinicians to
control MTX and improve patient outcomes. We are extremely pleased to have made
the successful submission of our Voraxaze marketing application in Europe. We
are now seeking agreement from the FDA to submit a similar application in the
US.`

[BrauchGeld]

Moin

Eigentlich hat Protherics fünf produkte auf den Markt,aber die zwei oben erwähnten sind die Umsatzstärksten.
Protherics ist eine aktie mit der man noch viel freude haben wird.

http://www.protherics.com/financials/Company_Presentations.a…

http://www.dac-fonds.de/xist4c/web/BIOTECH-FONDS_id_6062_.ht…

Protherics kaufen
Global Insider Investing

Die Experten von "Global Insider Investing" raten zum Kauf der Protherics-Aktie (ISIN GB0007029209 / WKN 883107).

Die Briten seien ein Nischenanbieter im Biotechbereich. Das Unternehmen habe fünf Produkte am Markt, die jeweils jährlich ca. einen Umsatz von 20 Mio. GBp abwerfen würden. Das wichtigste Produkt unter ihnen sei derzeit CroFab, welches ein Gegengift gegen Schlangenbisse darstelle. Es sei das einzige von der FDA zugelassene Gegengift bei Klapperschlangenbissen. Der Patentschutz laufe noch bis 2007. In der Forschungspipeline befänden sich noch Wirkstoffe gegen Sepsis, Krebs und Bluthochdruck. Nach Ansicht der Analysten von Durlacher hätten diese Produkte Blockbuster-Potenzial.

Der Newsflow dürfte im aktuellen Jahr nach Ansicht der Experten positiv ausfallen. Neue Produkteinführungen seien für das erste Halbjahr 2006 vorgesehen. An Protherics hätten sich bereits namenhafte Adressen wie Deutsche Asset Mgt., M&G Asset Mgt., Gartmore Investment und Framlington Investment beteiligt. Auch Director Tony Atkinson habe vor kurzem 300.000 eigene Aktien gekauft.

Anleger sollen ihm folgen und ebenfalls die Aktie von Protherics kaufen, so die Experten "Global Insider Investing".

[BrauchGeld]

Übermorgen gibts zahlen wenn die gut ausfallen dann ist der weg nach oben frei.
Die Aktie steigt schon im vorfeld :

http://finance.yahoo.com/q?s=pti.l

[BrauchGeld]

Hallo

Ich hoffe Ihr seid auch dabei

http://finance.yahoo.com/q?s=pti.l


Jawohl so gefällt es mir.

[BrauchGeld]

Hier ist der Affe genau richtig

http://www.rallymonkey.com/video/kenindex.swf

[BrauchGeld]

Partner für Cytofab ist Astrazeneca

Protherics PLC
08 December 2005

Protherics and AstraZeneca Announce Late Stage Licensing Agreement On
CytoFab(TM) For Treatment Of Sepsis


London, UK, Nashville, TN 8 December 2005 - Protherics, the biopharmaceutical
company focused on critical care and oncology, today announces an agreement with
AstraZeneca for the global development and commercialisation of Protherics`
anti-sepsis product CytoFab(TM). CytoFab(TM) is currently being prepared for a
single phase III registration study in severe sepsis in line with guidance
received at an end of phase II meeting with the US Food and Drug Administration
(FDA).


AstraZeneca will be responsible for developing CytoFab(TM), an anti-TNF-alpha
polyclonal antibody fragment (Fab) product, as a treatment for TNF-alpha
mediated diseases in man, with an initial target indication of severe sepsis.
Sepsis is a life-threatening condition resulting from uncontrolled severe
infections which affects an estimated three million people a year worldwide.
Under the terms of the agreement, AstraZeneca will undertake all clinical
development work for CytoFab(TM) and Protherics will be primarily responsible
for bulk drug manufacturing, including the supply of clinical trial material.
The agreement will become effective upon the expiration of the Hart-Scott-Rodino
waiting period in the US, which is anticipated early in 2006.


The agreement has a potential total deal value, excluding royalties, of
approximately £195 million to Protherics, including an initial payment of £16.3
million. In addition, AstraZeneca will make a £7.5 million equity investment in
Protherics to be paid in cash, at 68.24 pence per share, being a 30 percent
premium to the average middle market closing price of Protherics shares over the
three months prior to the date of the agreement. AstraZeneca will own
approximately 4.3 percent of Protherics` enlarged share capital.


Protherics will receive additional payments worth up to £171 million payable
upon the achievement of milestones. A significant proportion of these payments
are contingent on pre-approval milestones being achieved. There are no
milestone payments related to sales performance. Protherics will also receive
royalties on global product sales of 20 percent of net sales which reflect the
late stage development status and market potential of CytoFab(TM). Protherics
will also receive additional payments in return for the commercial supply of the
product and will invest to expand its manufacturing capacity accordingly.


AstraZeneca plans to start the pivotal phase III study for CytoFab(TM) in the US
and EU in 2007 following completion of improvements to the current manufacturing
process. Protherics has previously demonstrated in a phase IIb study that
CytoFab(TM) caused a marked reduction in TNF-alpha in the blood and lung tissues
of patients with severe sepsis, and that patients required on average five days`
less mechanical ventilation than when treated with placebo. In addition,
CytoFab(TM) showed an encouraging trend suggesting a survival benefit compared
to placebo and a favourable side-effect profile.


Approximately one third of patients with severe sepsis die from major organ
failure. Patients typically require mechanical ventilation and intensive care.
There is only one product currently available for the treatment of severe sepsis
and there remains a considerable unmet need for treatment of this
life-threatening condition.


Dr Andrew Heath, Chief Executive of Protherics, said: `We are delighted to
announce a major licensing deal with AstraZeneca for CytoFab(TM). AstraZeneca
has proven to be a focused and agile partner and as one of the leading
pharmaceutical companies in the world, it has the clinical, regulatory and
marketing strength to maximize the potential of CytoFab(TM). `


Dr John Patterson, Executive Director of Development, AstraZeneca, said: `
CytoFab(TM) is an exciting opportunity for AstraZeneca to extend its infection
franchise. By working together with Protherics, we now have the opportunity to
build on the excellent phase IIb data already generated. Our goal is to make
CytoFab(TM) the standard of care for patients with sepsis, improving their
chances of recovery and reducing their length of stay in intensive care. We
hope it will provide clinicians with a new means of addressing this devastating
condition and ultimately, help save lives.`

[BrauchGeld]

Hier nochmal auf Deutsch

08.12.2005 10:08
AstraZeneca steigt bei Protherics ein - Kooperation bei Wirkstoff CytoFab

Der britisch-schwedische Pharmakonzern AstraZeneca <AZN.ISE> <AZN.SSE> <ZEG.FSE> (Nachrichten/Aktienkurs) hat mit Protherics eine Forschungs- und Vertriebskooperation für den Wirkstoff CytoFab gegen Blutvergiftung abgeschlossen. Gleichzeitig beteiligte sich AstraZeneca mit 4,3 Prozent an dem Kooperationspartner, teilte der Pharmakonzern am Donnerstag in London mit.

AstraZeneca zahle für seine Beteiligung mit 68,24 Pence pro Aktie eine Prämie von 30 Prozent über dem mittleren Schlusskurs von Protherics in den letzten drei Monaten, teilte Astra weiter mit. Die Vereinbarung für CytoFab habe ein potenzielles Gesamtvolumen von 195 Millionen Pfund (286,65 Millionen Euro).

In Abhängigkeit von den Forschungserfolgen erhalte Protherics eine zusätzliche Zahlung von 171 Millionen Pfund. AstraZeneca will 2007 in den USA und Europa die zulassungsrelevante klinische Phase III für den Wirkstoff starten. Bei erfolgreicher Markteinführung erhalte Kooperationspartner Protherics 20 Prozent des Produktumsatzes./

[BrauchGeld]

Nochmal ein kurzes update:

Protherics gab zahlen und partner bekannt .
Halozyme hat die zulassung für hylenex erhalten .

Als nächstes ist Alizyme dran ich rechne mit positiven daten dort ist noch jede menge raus zuholen.